YASMIN ABAZA M.D. NPI 1033548383

NPI Details

Yasmin Abaza, M.D. is a hematology and oncology internal medicine in Chicago, IL with 16 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Yasmin Abaza, M.D. NPI is 1033548383. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

675 N SAINT CLAIR ST STE 21-100
CHICAGO, IL
ZIP 60611-970
Phone: (312) 695-0990
Fax: (312) 695-1106

The NPI 1033548383 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, carfilzomib, 1 mg (HCPCS:J9047)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, rituximab, 10 mg (HCPCS:J9312)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, octreotide, depot form for intramuscular injection, 1 mg (HCPCS:J2353)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Unclassified drugs (HCPCS:J3490)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Injection of drug or substance into vein (HCPCS:96374)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0221)
• Hospital discharge day management, 30 minutes or less (HCPCS:99238)
• Administration of influenza virus vaccine (HCPCS:G0008)

The enumeration date for this NPI number is 11/7/2013 and was last updated on 10/6/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: